16,023 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by HealthInvest Partners AB

HealthInvest Partners AB purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,023 shares of the medical research company’s stock, valued at approximately $4,615,000. Amgen accounts for approximately 3.6% of HealthInvest Partners AB’s investment portfolio, making the stock its 9th largest position.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Amgen by 62.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 276,553 shares of the medical research company’s stock valued at $79,653,000 after buying an additional 106,374 shares during the last quarter. West Paces Advisors Inc. boosted its position in Amgen by 41.6% in the 4th quarter. West Paces Advisors Inc. now owns 1,819 shares of the medical research company’s stock valued at $524,000 after buying an additional 534 shares during the last quarter. Marino Stram & Associates LLC boosted its position in Amgen by 0.7% in the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after buying an additional 34 shares during the last quarter. DGS Capital Management LLC boosted its position in Amgen by 1.7% in the 4th quarter. DGS Capital Management LLC now owns 3,291 shares of the medical research company’s stock valued at $948,000 after buying an additional 55 shares during the last quarter. Finally, Imprint Wealth LLC lifted its position in shares of Amgen by 41.8% during the fourth quarter. Imprint Wealth LLC now owns 1,411 shares of the medical research company’s stock worth $416,000 after purchasing an additional 416 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Amgen stock traded up $0.13 during mid-day trading on Tuesday, hitting $265.64. The company’s stock had a trading volume of 2,017,570 shares, compared to its average volume of 2,871,780. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $142.36 billion, a P/E ratio of 21.26, a P/E/G ratio of 2.53 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The stock’s fifty day moving average price is $279.63 and its two-hundred day moving average price is $281.52.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.09 earnings per share. Research analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.39%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AMGN shares. Raymond James started coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. The Goldman Sachs Group raised their target price on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and raised their target price for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. Finally, Oppenheimer reissued an “outperform” rating and issued a $350.00 target price on shares of Amgen in a report on Thursday, February 1st. Ten analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.